Overall Survival and Clinicopathological Characteristics of Patients with Breast Cancer in Relation to the Expression Pattern of HER-2, IL-6, TNF-α and TGF-β1 |
Tripsianis, Gregory
(Laboratory of Medical Statistics, Medical School, Democritus University of Thrace)
Papadopoulou, Evropi (Laboratory of Biochemistry, Medical School, Democritus University of Thrace) Romanidis, Konstantinos (Second Department of Surgery, Medical School, Democritus University of Thrace) Katotomichelakis, Michael (Department of Otorhinolaryngology, Medical School, Democritus University of Thrace) Anagnostopoulos, Kostas (Laboratory of Biochemistry, Medical School, Democritus University of Thrace) Kontomanolis, Emmanuel (Department of Obstetrics and Gynecology, Medical School, Democritus University of Thrace) Botaitis, Sotirios (Second Department of Surgery, Medical School, Democritus University of Thrace) Tentes, Ioannis (Laboratory of Biochemistry, Medical School, Democritus University of Thrace) Kortsaris, Alexandros (Laboratory of Biochemistry, Medical School, Democritus University of Thrace) |
1 | Kong Y, Dai S, Xie X, et al (2012). High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol, 138, 275-84. DOI |
2 | Kostler W, Schwab B, Singer C, et al (2004). Monitoring serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res, 10, 1618-24. DOI ScienceOn |
3 | Lin W, Karin M (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest, 117, 1175-83. DOI ScienceOn |
4 | Lipton A, Ali S, Leitzel K, et al (2002). Elevated serum Her-2/neu level predicts decreased response to hormone therapyin metastatic breast cancer. J Clin Oncol, 20, 1467-72. DOI ScienceOn |
5 | Locksley R, Killeen N, Lenardo M (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104, 487-501. DOI ScienceOn |
6 | Ma L, Yang H, Han X, et al (2012). Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer. Chinese Med J, 125, 4104-10. |
7 | MacEwan D (2002). TNF receptor subtype signalling: differences and cellular consequences. Cell Signal, 14, 477-92. DOI ScienceOn |
8 | Massague J, Cheifetz S, Laiho M, et al (1992). Transforming growth factor-beta. Cancer Surv, 12, 81-103. |
9 | Moore R, Owens D, Stamp G, et al (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 5, 828-31. DOI ScienceOn |
10 | Nicolini A, Carpi A, Rossi G (2006). Cytokines in breast cancer. Cytokine Growth Factor Rev, 17, 325-37. DOI ScienceOn |
11 | Panis C, Herrera A, Victorino V, Aranome A, Cecchini R (2013). Screening of circulating TGF- levels and its clinicopathological significance in human breast cancer. Anticancer Res, 33, 737-42. |
12 | Papadopoulou E, Anagnostopoulos K, Tripsianis G, et al (2008a). Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Neoplasma, 55, 229-38. |
13 | Papadopoulou E, Tripsianis G, Anagnostopoulos K, et al (2008b). The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma, 55, 113-21. |
14 | Papadopoulou E, Tripsianis G, Anagnostopoulos K, et al (2010). Significance of serum tumor necrosis factor-alpha and its interaction with HER-2 codon 655 polymorphism on breast cancer outcome. Int J Biol Markers, 25, 126-35. |
15 | Parker C (2004). Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol, 5, 101-6. DOI ScienceOn |
16 | Perera M, Tsang C, Distel R, et al (2010). TGF-beta1 interactome: metastasis and beyond. Cancer Genomics Proteomics, 7, 217-29. |
17 | Ravishankaran P, Karunanithi R (2011). Clinical significance of preoperative serum interleukin-6 and Creactive protein level in breast cancer patients. World J Surg Oncol, 9, 18. DOI ScienceOn |
18 | Reiss M, Barcellos-Hoff M (1997). Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat, 45, 81-95. DOI ScienceOn |
19 | Rustin G (2003). Use of CA 125 to assess response to new agents in ovarian cancer trials. J Clin Oncol, 21, 187-93. DOI ScienceOn |
20 | Ross J, Fletcher J, Bloom K, et al (2004). Targeted therapy in breast cancer: the HER-2/neu, gene and protein. Mol Cell Proteomics, 3, 379-98. DOI ScienceOn |
21 | Samuel S, Hurta R, Kondaiach P, et al (1992). Autocrine induction of tumor protease production and invasion by a metallothionen-regulated TGF-1. EMBO J, 11, 1599-605. |
22 | Samy N, Ragab H, El Maksoud N, Shaalan M (2010). Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark, 6, 63-72. DOI |
23 | Sharif M, Mamoon N, Mushtaq S, Khadim M (2010). Age related association of Her-2/neu with prognostic markers in female breast carcinoma. J Coll Physicians Surg Pak, 20, 590-4. |
24 | Sharma R, Anker S (2002). Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol, 85, 161-71. DOI ScienceOn |
25 | Sheen-Chen S, Chen H, Sheen C, et al (2001). Serum levels of Transforming growth factor-1 in patients with breast cancer. Arch Surg, 136, 937-9. DOI ScienceOn |
26 | Siegel P, Massague J (2003). Cytostatic and apoptotic actions of TGF-1 in homeostasis and cancer. Cancer, 3, 807-20. |
27 | Thomson A, Lotze M (2003). The cytokine handbook" (4th ed), Academic Press, London. |
28 | Todorovi.-Rakovi. N (2008). TGF- and HER2/ErbB2 and Breast Cancer Progres-sion. In "Transforming Growth Factor- in Cancer Therapy, Volume II," Humana Press, 141-51. |
29 | Ueki N, Nakazato M, Ohkawa T, et al (1992). Excessive production of transforming growth factor-1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta, 1137, 189-96. DOI ScienceOn |
30 | Tripsianis G, Papadopoulou E, Botaitis S, et al (2012). A Diagnostic and prognostic significance of serum IL-6 levels in breast cancer. JP J Biostatistics, 1-2, 59-77. |
31 | Vilcek J, Lee T (1991). Tumour necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem, 266, 7313-16. |
32 | Wang S (2011). The functional crosstalk between HER2 tyrosine kinase and TGF- signaling in breast cancer malignancy. J Signal Transduction, 2011, 804236. |
33 | Wang X, Shao X, Chen Z, et al (2012). Circulating HER2 extracellular domain (ECD) levels are associated with progression-free survival in metastatic breast cancer patients. Cancer Res, 72. |
34 | Yarden Y, Sliwkowski M (2001). Untangling the ErbB signaling network. Nat Rev Mol Cell Biol, 2, 127-37. DOI ScienceOn |
35 | Zhou B, Hu M, Miller S, et al (2000). HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kB pathway. J Biol Chem, 275, 8027-31. DOI ScienceOn |
36 | Ali S, Leitzel K, Chinchilli V, et al (2002). Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem, 48, 1314-20. |
37 | Aggarwal B, Vijayalekshmi R, Sung B (2009). Targeting infl ammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res, 15, 425-30. DOI ScienceOn |
38 | Al-Hassan A, Al-Ghurabi B, Al-Karkhi I (2012). Prognostic value of proinflammatory cytokines in breast cancer. J Biomol Res Ther, 1, 104. |
39 | Ali H, Mahdi N, Al-Jowher M (2012). Serum ig and cytokine levels in women with breast cancer before and after mastectomy. Med J Islamic World Acad-emy Sci, 20, 121-9. |
40 | Alsuhail R (2008). Serum level of interleukin 6 and tumor necrosis factor in Iraqi breast cancer patients. MMJ, 7, 34-6. |
41 | Alvarez B, Quinn L, Busquets S, et al (2002). Tumor necrosis factor-alpha exerts interleukin-6-dependent and independent effects on cultured skeletal muscle cells. Biochim Biophys Acta, 1542, 66-72. DOI ScienceOn |
42 | Auvinen P, Lipponen P, Johansson R, et al (1995). Prognostic significance of TGF-1 and TGF-2 expressions in female breast cancer. Anticancer Res, 15, 2627-32. |
43 | Azizun-Nisa, Bhurgri Y, Raza F, Kayani N (2008). Comparison of ER, PR & HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev, 9, 553-6. |
44 | Badache A, Hynes N (2001). Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res, 61, 383-91. |
45 | Bewick M, Chadderton T, Conlon M, et al (1999). Expression of cerbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant, 24, 377-84. DOI |
46 | Balkwill F (2002). Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev, 13, 135-41. DOI ScienceOn |
47 | Balkwill F (2009). Tumour necrosis factor and cancer. Nat Rev Cancer, 9, 361-71. DOI ScienceOn |
48 | Ben-Baruch A (2003). Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res, 5, 31-6. DOI |
49 | Bloom H, Richardson W (1957). Histological grading and prognosis in breast cancer. Br J Cancer, 11, 359-77. DOI ScienceOn |
50 | Bromberg J, Wrzeszczynska M, Devgan G, et al (1999). Stat3 as an oncogene. Cell, 98, 295-303. DOI ScienceOn |
51 | Carney W, Neumann R, Lipton A, et al (2003). Potential utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem, 49, 1579-98. DOI ScienceOn |
52 | Chavey C, Bibeau F, Gourgou-Bourgade S, et al (2007). Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res, 9, 15. |
53 | Chod J, Zavadova E, Halaska M (2008). Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol, 29, 613-6. |
54 | Duffy M (2001). Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem, 47, 624-30. |
55 | Colomer R, Llombard-Cussac A, Lluch A, et al (2004). Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER-2 extracellular domain. Ann Oncol, 15, 201-6. DOI ScienceOn |
56 | Dave H, Shah M, Trivedi S, Shukla S (2012). Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients. Int J Biol Markers, 27, 53-9. DOI ScienceOn |
57 | Derynck R, Goeddel D, Ulrich A, et al (1987). Synthesis of messenger RNAs for transforming growth factors and and the epidermal growth factor receptor by human tumors. Cancer Res, 47, 707-12. |
58 | Duffy M (2002). Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem, 48, 1194-7. |
59 | Duffy M (2006). Serum tumor markers in breast cancer: are they of clinical value? Clin Chem, 52, 345-51. DOI ScienceOn |
60 | Elston C, Ellis I, Pinder S (1999). Pathological prognostic factors in breast cancer. Crit Rev Oncol Haematol, 31, 209-23. DOI ScienceOn |
61 | Esteva F, Cheli C, Fritsche H, et al (2005). Clinical utility of serum HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res, 7, 436-43. DOI ScienceOn |
62 | Fehm T, Jager W, Kramer S, et al (2004). Prognostic significance of serum HER2 and CA15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res, 24, 1987-92. |
63 | Grivennikov S, Karin M (2011). Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis, 70, 104-8. DOI ScienceOn |
64 | Fisher P, Hancock B (1997). Gestational trophoblastic disease and their treatment. Cancer Treat Rev, 23, 1-16. DOI ScienceOn |
65 | Grivennikov S, Greten F, Karin M (2010). Immunity, inflammation, and cancer. Cell, 140, 883-99. DOI ScienceOn |
66 | Grivennikov S, Karin M (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev, 21, 11-9. DOI ScienceOn |
67 | Harris L, Liotcheva V, Broadwater G, et al (2001). Comparison of methods of meas-uring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol, 19, 1698-706. DOI |
68 | Heikkila K, Ebrahim S, Lawlor D (2008). Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer, 44, 937-45. DOI ScienceOn |
69 | Isaacs C, Stearns V, Hayes D (2001). New prognostic factors for breast cancer. Semin Oncol, 28, 53-67. DOI |
70 | Kayacan O, Karnak D, Beder S, et al (2006). Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol, 29, 328-35. DOI ScienceOn |
71 | Knupfer H, Preiss R (2007). Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat, 102, 129-35. DOI ScienceOn |